Mereo BioPharma

Mereo BioPharma is a rare disease biopharmaceutical company built around a distinctive model: acquiring and developing clinical-stage assets that larger organisations have deprioritised, then advancing them through late-stage trials and towards commercialisation.

Headquartered in London, United Kingdom, and listed on Nasdaq (MREO) as well as the London Stock Exchange, Mereo has assembled a focused pipeline centred on conditions with significant unmet medical need. The company's lead programmes have targeted areas including osteogenesis imperfecta, a severe genetic bone disorder, and oncology indications, reflecting a dual strategy that spans rare diseases and specialist cancer therapy.

Mereo's approach differs from traditional drug developers in that it sources compounds that have already generated meaningful clinical data, reducing early-stage risk while concentrating resources on the late-stage development work most likely to generate regulatory submissions and, ultimately, patient access. This model positions the company as an efficient deployer of late-phase capital rather than a broad discovery organisation.

The company works with established clinical and regulatory frameworks across the United States and Europe, engaging with both the FDA and EMA as its programmes advance. Its Nasdaq listing has given Mereo access to a broad pool of US-based biotech investors, while its London roots keep it connected to the European rare disease and specialist pharma community.

With a pipeline concentrated on rare and serious conditions, Mereo BioPharma represents a category of specialist late-stage developer that has become an increasingly recognised part of the global biopharmaceutical landscape, bridging the gap between large-company asset disposal and patient need.

Further information is available at mereobiopharma.com.